Skip to content

ALIVER is a project that has received funding from the European Union’s Horizon 2020 research and innovation programme, after 25 years of experimental research and data collection on extracorporeal perfusion as a therapy option in liver failure. The ALIVER Consortium has developed and optimised a novel ‘liver dialysis device’, Dialive™.

About EASL and the ALIVER Consortium

The ALIVER Consortium of 11 institutions from seven European countries developed an innovative liver dialysis machine called Dialive™. This device helps the liver to regenerate naturally or, when that does not prove possible, keeps patients alive and healthy until a donated liver becomes available.

This project received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 733057. As a Swiss partner in the ALIVER project, EASL received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 16.0204.

The consortium is led by University College London (UCL), and includes EASL, the European Foundation for the Study of Chronic Liver Failure (EF Clif), and Yaqrit Ltd, a life sciences company and intellectual property owner of Dialive™, amongst others. EASL serves as the dissemination arm of several EU-funded projects, including in the ALIVER Consortium from 2017 to 2020, providing dissemination, exploitation, and communication activities.


Disclaimer as of 16 March 2022

The data relating to ALIVER described on the EC website should be considered a “preliminary analysis”’ and although it is based on a fully audited and monitored Clinical Study Report,  it has not been fully peer reviewed and therefore not published.  Further details on the ALIVER clinical study outcomes can be found on with details of the clinical study protocol on  the website  and a copy of the Clinical Study Report is available on request from the Sponsor: Yaqrit Limited (


Back To Top